No insider purchase over the last 90 days. The latest, by 박철세, was filed 29 May 2026.
BioNote, Inc.: what insiders have been doing
BioNote, Inc. is a Health Care company. Its directors and officers file their transactions with DART (FSS). From 1 November 2025 to 1 November 2026, the disclosure feed for BioNote, Inc. logged 8 filings by 5 insiders.
The flow runs one way only: 4 insiders bought (6 purchases totalling €1.5M) and nobody sold on the market. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 2 board members and 1 chief executive. The largest single trade was a purchase of €882k by 조병기, published on 10 March 2026, equal to 0.30% of the market capitalisation.
Within a 30-day window, 2 purchases overlapped with buying by a second insider. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 29 May 2026, 163 days ago. The median gap between a trade and its publication by DART (FSS) is 5 days. The shorter that gap, the sooner other investors can see what insiders have done.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 8 filings, this issuer sits above that mark. Looking back to 2022, when coverage begins, insiders filed 15 purchases and 1 sale.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- -2.2%Entry ₩4,755 · Close 30 Oct 2026 ₩4,650
- -8.3%Entry ₩5,070 · Close 30 Oct 2026 ₩4,650
- -8.3%Entry ₩5,070 · Close 30 Oct 2026 ₩4,650
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 1,950 shares@ ₩5,090.000.0019% mcap30.7% of flowShareKRXDART:20260529000041Canonical exit: 25 Aug 2026 (T+90)
- 160,000 shares@ ₩4,678.000.14% mcap100.0% of flowShareKRXDART:20260421000385Canonical exit: 14 Jul 2026 (T+90)
- 100 shares0.0001% mcap0.1% of flowKRXDART:20260421000407Canonical exit: 14 Jul 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- 66,000 shares0.068% mcap99.9% of flowKRXDART:20260310003020Canonical exit: 3 Jun 2026 (T+90)
- 4,000 shares@ ₩5,449.000.0043% mcap69.3% of flowShareKRXDART:20260310002960Canonical exit: 3 Jun 2026 (T+90)
- 320,000 shares@ ₩4,687.000.30% mcap100.0% of flowShareKRXDART:20260310002946Canonical exit: 3 Jun 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- 60,000 sharesKRXDART:20250205000331Canonical exit: 6 May 2025 (T+90)
- 10,000,000 sharesShareKRXDART:20250205000338Canonical exit: 6 May 2025 (T+90)
- 10,000,000 sharesShareKRXDART:20250205000333
- ●Executives0DART
- ●Executives0DART
- 6,729,843 sharesShareKRXDART:20240415000383Canonical exit: 11 Jul 2024 (T+90)
- 60,000 sharesKRXDART:20230901000455Canonical exit: 31 Oct 2023 (T+90)
- 60,000 sharesKRXDART:20230831001264Canonical exit: 11 Oct 2023 (T+90)
- 60,000 sharesKRXDART:20230804000090Canonical exit: 31 Oct 2023 (T+90)
- ShareKRXDART:20230802000312
- ShareKRXDART:20230725000268
- 60,000 sharesKRXDART:20230720000416Canonical exit: 11 Oct 2023 (T+90)
- ShareKRXDART:20230717000214
- 60,000 sharesKRXDART:20221229000702Canonical exit: 29 Mar 2023 (T+90)
- ShareKRXDART:20221228000142
25 of 33 declarations
About BioNote, Inc.
BioNote is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on the development of biological and diagnostic products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
